Tri Chemical Laboratories Inc. (TYO:4369)
3,800.00
+285.00 (8.11%)
Jun 15, 2026, 3:30 PM JST
Tri Chemical Laboratories Revenue
Tri Chemical Laboratories had revenue of 7.49B JPY in the quarter ending April 30, 2026, with 13.98% growth. This brings the company's revenue in the last twelve months to 24.80B, up 11.71% year-over-year. In the fiscal year ending January 31, 2026, Tri Chemical Laboratories had annual revenue of 23.88B with 26.33% growth.
Revenue (ttm)
24.80B
Revenue Growth
+11.71%
P/S Ratio
4.61
Revenue / Employee
79.24M
Employees
313
Market Cap
114.23B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jan 31, 2026 | 23.88B | 4.98B | 26.33% |
| Jan 31, 2025 | 18.91B | 7.66B | 68.10% |
| Jan 31, 2024 | 11.25B | -2.56B | -18.52% |
| Jan 31, 2023 | 13.80B | 2.23B | 19.26% |
| Jan 31, 2022 | 11.57B | 1.77B | 18.09% |
| Jan 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 31, 2012 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 31, 2011 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sakata INX | 261.73B |
| Takasago International | 225.09B |
| Kureha | 161.69B |
| Ishihara Sangyo Kaisha,Ltd. | 154.90B |
| Konishi | 136.57B |
| Sanyo Chemical Industries | 127.86B |
| Sk Kaken | 109.71B |
| Okamoto Industries | 108.04B |
Tri Chemical Laboratories News
- 17 days ago - Tri Chemical Laboratories Quarterly report: Q1 2027 - Filings
- 3 months ago - Tri Chemical Laboratories Quarterly report: Q4 2026 - Filings
- 7 months ago - Tri Chemical Laboratories Quarterly report: Q3 2026 - Filings
- 10 months ago - Tri Chemical Laboratories Quarterly report: Q2 2026 - Filings